SCHEMBL429330

SCHEMBL429330

N#CNC(=N)NCCCCCCNC(=N)NC#N

nearest known ligand 0.32

Predicted protein targets (top 9)

geneUniProtsupporting neighboursconfidence
SMN1; SMN2 Q16637 2/20 0.32
MEN1 O00255 1/20 0.32
CYP1A2 P05177 1/20 0.32
KMT2A Q03164 1/20 0.32
KDM4E B2RXH2 1/20 0.32
MAPK1 P28482 1/20 0.32
HIF1A Q16665 1/20 0.32
ALDH1A1 P00352 1/20 0.31
DNM1 Q05193 2/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL8755558 1.00 SMN1; SMN2 (0.32) SMN1; SMN2MEN1CYP1A2KMT2AKDM4E
SCHEMBL18597314 0.94
SCHEMBL8755597 0.93
SCHEMBL11726259 0.90 EPHX1 (0.45)
SCHEMBL1937316 0.90 EPHX1 (0.45)
SCHEMBL1937986 0.90 EPHX1 (0.45)
SCHEMBL1937657 0.90 EPHX1 (0.45)
SCHEMBL11810751 0.90 EPHX1 (0.45)
SCHEMBL12669343 0.90 EPHX1 (0.45)
SCHEMBL11125409 0.90 EPHX1 (0.45)

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 37 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20210087337-A1 COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS VYOME THERAPEUTICS LIMITED (IN) 2021-03-25 US claimed
US-20190373895-A1 BRANCHED POLYMERIC BIGUANIDE COMPOUNDS AND THEIR USES CHEN HWANG HSING (US) 2019-12-12 US claimed
EP-2306816-B1 Use of topical compositions for the preservation of a human or animal body ARKEMA FRANCE (FR) 2015-04-08 EP claimed
US-20110104097-A1 TOPICAL COMPOSITIONS FOR THE PRESERVATION OF A HUMAN OR ANIMAL BODY ARKEMA FRANCE (FR) 2011-05-05 US claimed
JP-1071846-A None JP disclosed
US-20250359547-A1 ALKOXYLATED ALKANOLS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS BASF SE (DE) 2025-11-27 US disclosed
WO-2024013193-A1 ALKOXYLATED ALKANOLS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS BASF SE (DE) 2024-01-18 WO disclosed
WO-2023170160-A1 POLYMERIC IMIDAZOLIUM COMPOUNDS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS BASF SE (DE) 2023-09-14 WO disclosed
US-11044912-B2 Branched polymeric biguanide compounds and their uses CHEN HWANG HSING (US) 2021-06-29 US disclosed
EP-3040007-B2 BIOCIDE-FREE, PREWETTED SPONGE CLOTH KALLE GMBH (DE) 2021-06-16 EP disclosed
US-20210087337-A1 COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS VYOME THERAPEUTICS LIMITED (IN) 2021-03-25 US disclosed
US-20210087337-A1 COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS VYOME THERAPEUTICS LIMITED (IN) 2021-03-25 US disclosed
EP-0668885-A4 POLYMERIC BIGUANIDES. STOCKEL RICHARD F (US) 1998-09-30 EP disclosed
EP-0643044-B1 Bis-biguanide compound useful as a disinfectant MITSUBISHI MATERIALS CORP (JP) 1997-05-07 EP disclosed
EP-0668885-A1 POLYMERIC BIGUANIDES STOCKEL, Richard F. (US) 1995-08-30 EP disclosed
EP-0305721-B1 PROCESS FOR PREPARING HEXAMETHYLENE BIS-DICYANIDE DIAMIDE Degussa Aktiengesellschaft (DE) 1991-10-16 EP disclosed
WO-1990011315-A1 POLYMERIC BIGUANIDES STOCKEL RICHARD F (US) 1990-10-04 WO disclosed
EP-0305721-A1 Process for preparing hexamethylene bis-dicyanide diamide Degussa Aktiengesellschaft (DE) 1989-03-08 EP disclosed
EP-0232250-A1 METHODS AND SOLUTION FOR DESINFECTING AND PRESERVING CONTACT LENSES. BAUSCH & LOMB (US) 1987-08-19 EP disclosed
WO-1987000437-A1 METHODS FOR DESINFECTING AND PRESERVING CONTACT LENSES BAUSCH & LOMB INCORPORATED (US) 1987-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250359547-A1 ALKOXYLATED ALKANOLS FOR ENHANCING THE ACTIVITY OF ANTIMICROBIAL AGENTS CAT, LPO, ALKBH1 SMN1; SMN2 3729/4885MEN1 3783/4885CYP1A2 158/4885
US-11044912-B2 Branched polymeric biguanide compounds and their uses PUF60, XRCC6, PCNA SMN1; SMN2 3255/4885MEN1 975/4885CYP1A2 1462/4885
US-20190373895-A1 BRANCHED POLYMERIC BIGUANIDE COMPOUNDS AND THEIR USES PUF60, XRCC6, PCNA SMN1; SMN2 3255/4885MEN1 975/4885CYP1A2 1462/4885
US-20210087337-A1 COMPOUNDS, COMPOSITIONS AND METHODS RELATED TO ANTIMICROBIAL APPLICATIONS CUTA, GMPS, MMP8 SMN1; SMN2 3207/4885MEN1 4743/4885CYP1A2 2367/4885
US-20110104097-A1 TOPICAL COMPOSITIONS FOR THE PRESERVATION OF A HUMAN OR ANIMAL BODY FUCA1, PIGS, UNG SMN1; SMN2 941/4885MEN1 2840/4885CYP1A2 2450/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.